Impact of using a mobile protective pod (MOBY) on the quality of life within pediatric hematooncologic patients being severely immunocompromised – prospective cohort study of a single center trial

Impact of using a mobile protective pod (MOBY) on the quality of life within pediatric hematooncologic patients being severely immunocompromised – prospective cohort study of a single center trial - MOBY-Study

Status

Recruiting

Phases

Unknown

Study type

Interventional

Source

DRKS

Registry ID

DRKS00032818

Enrollment

Registered

2023-10-06

Start date

2024-09-23

Completion date

Unknown

Last updated

2025-04-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Immunocompromised pediatric patients undergoing allogeneic or autologous hematopoietic stem cell transplantation or receiving high-dose chemotherapy

Interventions

Group 1: Immunocompromised pediatric patients undergoing allogeneic or autologous hematopoietic stem cell transplantation or receiving high-dose chemotherapy are using a mobile protective pod (MOBY).

Eligibility

Sex/Gender

All

Age

3 Years to 17 Years

Inclusion criteria

Inclusion criteria: Patients are undergoing allogeneic/autologous hematopoietic stem cell transplantation OR high-dose chemotherapy Age 3 - 17 years at time of inclusion Body weight of patient (and in age group 3-6 years plus companion) is less than 150kg Sufficient German language skills of the participating patients and their parents Written consent from the patient(s) or legal representatives to participate in the present study and to pass on pseudonymized data as part of the documentation Availability for three-month follow-up

Exclusion criteria

Exclusion criteria: Severe acute infection, such as sepsis at inclusion Missing physical mobility of the patient, such as missing ability to sit Patients with severe claustrophobia Acute severe psychiatric disorder before inclusion Severe mental disability Severe language barriers of patient and/or custodians

Design outcomes

Primary

Measure	Time frame
Quality of life assessed in semi-structured qualitative interviews and using the KINDL(R) questionnaire (collected before the first use of MOBY and after 4-6 uses of MOBY)	—

Secondary

Measure	Time frame
Occurrence of febrile neutropenia (number of episodes) MOBY usage time per patient Day of first mobilization after stem cell transplant/high-dose chemotherapy Duration of parenteral nutrition after stem cell transplantation/high-dose chemotherapy Inpatient readmission to hospital (up to three months after discharge) Post-traumatic symptoms in the follow-up after 3 months (assessed by the CRIES-8)	—

Countries

Germany

Contacts

Public ContactGeorg Seifert

Charité - Universitätsmedizin Berlin

georg.seifert@charite.de+49 030 450 666 087

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Feb 4, 2026